MT 2990

Drug Profile

MT 2990

Alternative Names: MT-2990

Latest Information Update: 03 Jul 2017

Price : $50

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Unspecified

Most Recent Events

  • 17 May 2017 Phase-I clinical trials in Undefined indication (In volunteers) in Netherlands (IV) (NCT03156738)
  • 15 May 2017 Mitsubishi Tanabe Pharma Corporation plans a phase I trial in Healthy volunteers in Netherlands (IV) (NCT03156738)
  • 15 May 2017 Preclinical trials in Undefined indication in Japan (IV) before May 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top